/
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as Gilead, the company, we, our or us ) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, includ…
Margins and capital returns are both well above average: 34.04% operating margin, ROIC at 18.41%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue growth slowed to 2.4%, essentially flat. This is a business that needs a catalyst.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$29.74B
▲ +2.4% YoY
Net Income (TTM)
$9.22B
▲ +1672.9% YoY
Op. Margin
34.88%
▲ +28.3pp YoY
ROIC
19.15%
▲ +15.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$10.23B
▼ -8.2% YoY
Op. Cash Flow (TTM)
$10.81B
▼ -7.5% YoY
Net Debt
$14.53B
Cash & Equiv.
$7.64B
5Y CAGR: +3.6%
5Y CAGR: +4.7%
Continue Research